Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders: IOIS Guidelines

253 Pages·2014·6.47 MB·English

by  Uwe Pleyer

Uwe Pleyer · Jorge L. Alió · Talin Barisani-Asenbauer
Phuc Le Hoang · Narsing A. Rao Editors
Immune Modulation and
Anti-Infl ammatory Therapy
in Ocular Disorders
IOIS Guidelines
123
Immune Modulation and Anti-
Infl ammatory Therapy in Ocular
Disorders

Uwe Pleyer • Jorge L. A lió
Talin Barisani-Asenbauer
Phuc Le Hoang • Narsing A. Rao
Editors
Immune Modulation
and Anti-Infl ammatory
Therapy in Ocular
Disorders
IOIS Guidelines
Editors
Uwe Pleyer Phuc Le Hoang
Department of Ophthalmology Department of Ophthalmology
Charité Campus Virchow-Klinikum Pitié-Salpêtrière’s University Hospital
Berlin Paris
Germany France
Jorge L. Alió Narsing A. Rao
Division of Ophthalmology Doheny Eye Institute
Miguel Hernandez University University of Southern California Keck
Vissum-Instituto Oftalmologico de School of Medicine
Alicante Los Angeles, CA
Spain USA
Talin Barisani-Asenbauer
Centre of Ocular Infl ammation
and Infection OCUVAC
Medical University of Vienna Laura
Bassi Centre of Expertise
Vienna
Austria
ISBN 978-3-642-54349-4 ISBN 978-3-642-54350-0 (eBook)
DOI 10.1007/978-3-642-54350-0
Springer Heidelberg New York Dordrecht London
Library of Congress Control Number: 2014938996
© Springer-Verlag Berlin Heidelberg 2014
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed. Exempted from this
legal reservation are brief excerpts in connection with reviews or scholarly analysis or material
supplied specifi cally for the purpose of being entered and executed on a computer system, for
exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is
permitted only under the provisions of the Copyright Law of the Publisher's location, in its
current version, and permission for use must always be obtained from Springer. Permissions for
use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable
to prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specifi c statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility
for any errors or omissions that may be made. The publisher makes no warranty, express or
implied, with respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
We dedicate this book to our teachers: patients and colleagues.
In particular to the members of IOIS in their efforts to care,
fi ght, and teach on the many aspects of ocular infl ammation.

Pref ace
T his IOIS guideline on “immune modulation and anti-infl ammatory therapy
in ocular disorders” is a continuation of our efforts to provide relevant details
on ocular infl ammations to the practicing clinician. All segments of the eye
can be affected by often destructive and sight-threatening infl ammatory dis-
eases. Frequently the management of such disorders provides a challenge to
physicians to handle them and for patients to follow instructions in avoiding
complications of therapy. The rapid advance of our knowledge base and
development of new immunomodulatory agents have culminated in a new era
of medical care. Such advances allow us proper management of ocular
infl ammatory conditions.
This IOIS guideline on treatment of ocular infl ammation is intended to
provide the practitioner evidence-based practical information on therapeutic
interventions based on recent advances in immunomodulatory agents.
Therapeutic interventions in the broad area of ocular surface disorders, post-
surgical noninfectious infl ammations, uveitis related to systemic autoimmune
disorders, and organ-specifi c infl ammatory and immune diseases are covered
by international experts. In addition, these experts provided relevant discus-
sions on mechanisms underlying these conditions by incorporating results of
most recent research literature.
We are grateful to all authors who have contributed to this edition of the
IOIS guidelines and invested their valuable time with primary goal of provid-
ing succinctly proper and cutting-edge management of ocular infl ammations.
We believe that this book by providing proper guidelines for the management
of the ocular infl ammatory disorders will help both clinicians and patients
suffering from potentially preventable blindness globally.
Berlin, Germany Uwe Pleyer , MD, FEBO
Los Angeles, CA, USA Narsing Rao
vii

Contents
1 Ocular Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Andrea Leonardi and Neal P. Barney
2 Immune Modulation in Ocular Mucous
Membrane Pemphigoid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
John Kenneth George Dart and Valerie P.J. Saw
3 Diagnosis and Management of Scleritis. . . . . . . . . . . . . . . . . . . 41
Claire Hooper and Peter McCluskey
4 Noninfectious Infl ammation in Cataract Surgery . . . . . . . . . . 63
Nick Mamalis and Stanley R. Fuller
5 Corneal Infl ammation Following Excimer Laser Surgery. . . . 75
Jaime Javaloy, Jorge L. Alió, and Alfredo Vega Estrada
6 Prevention and Treatment of Transplant Rejection
in Keratoplasty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Uwe Pleyer and Anna-Karina Brigitte Maier
7 Immunomodulation Against Infl ammatory
Postkeratoplasty Neovascularisation . . . . . . . . . . . . . . . . . . . . . 117
Björn Bachmann and Claus Cursiefen
8 Treatment of Infl ammation Secondary
to Vitreoretinal Surgery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Carolina Arruabarrena Sánchez and Marta S. Figueroa
9 Treatment of Intermediate Uveitis. . . . . . . . . . . . . . . . . . . . . . . 135
Elisabetta Miserocchi, Umberto De Benedetto,
and Giulio Modorati
10 Posterior Uveitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Piergiorgio Neri, Ilir Arapi, Uwe Pleyer, Moncef Khairallah,
Soumyava Basu, Michele Nicolai, Vittorio Pirani,
Alfonso Giovannini, and Cesare Mariotti
11 Cystoid Macular Edema . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
Marc D. de Smet
12 Safety of Immunosuppressive Therapy for Eye Diseases. . . . . 231
Dana M. Hornbeak and John H. Kempen
ix